Oxidative and Nitrosative Stress in Stable Renal Transplant Recipients with Respect to the Immunosuppression Protocol - Differences or Similarities?

Journal of Medical Biochemistry

Volumn 34, Issue 3, 2015, Pages 295-303

  Cvetković, Tatjana ^a,b   Veličković Radovanović, Radmila ^a,b   Stojanović, Dijana ^a   Stefanović, Nikola ^a   Ignjatović, Aleksandra ^c   Stojanović, Ivana ^a   Sladojević, Nikola ^d   Pavlović, Dušica ^a  

^a UNIVERSITY OF NI   (Serbia)

^b University Clinical Centre of Nis   (Serbia)

^c Institute for Public Health   (Serbia)

^d Box 1500   (United States)

Author keywords

ADMA; nitrozativni stres; oksidativni stres; SDMA; transplantacija bubrega

Indexed keywords

6 N,N' DIMETHYLARGININE; ADVANCED OXIDATION PROTEIN PRODUCT; CATALASE; CYCLOSPORIN A; MYCOPHENOLATE MOFETIL; N(G),N(G) DIMETHYLARGININE; NITRIC ACID DERIVATIVE; TACROLIMUS; THIOBARBITURIC ACID REACTIVE SUBSTANCE; THIOL GROUP;

ADULT; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; ENZYME ACTIVITY; ERYTHROCYTE LEVEL; FEMALE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NITROSATIVE STRESS; OXIDATIVE STRESS;

EID: 84938341987     PISSN: 14528258     EISSN: 14528266     Source Type: Journal    
DOI: 10.2478/jomb-2014-0047     Document Type: Article

References (64)

1. Garcia GG, Harden P, Chapman J. The Global Role of Kidney Transplantation. Am J Nephrol 2012; 35: 259-64.
2. Morales JM, MarcénR, AndrésA, Molina MG, Castillo DD, Cabello M, et al. Renal transplantation in the modern immunosuppressive era in Spain: four-year results from a multicenter database focus on post-transplant cardiovascular disease. Kidney Int 2008; 74: 94-9.
3. Kasiske BL. Risk factor for accelerated atherosclerosis in renal transplant recipients. Am J Med 1988; 84: 985-92.
4. La Manna G, Lanci N, Della Bella E, Comai G, Cappu-c cilli ML, Nisi K, et al. Reduction of Oxidative Damage Reflects a Better Kidney Transplantation Outcome. Am J Nephrol 2011; 34: 496-504.
5. Dimeny E. Cardiovascular disease after renal transplantation. Kidney Int 2002; 61 Supp 80, 78-84.
6. Himmelfarb J. Uremic toxicity, oxidative stress, and hemo dialysis as renal replacement therapy. Semin Dial 2009; 22: 636-43.
7. Floccari F, Aloisi C, CrascíE, Sofi T, Campo S, Tripodo D, et al. Oxidative stress and uremia. Med Res Rev 2005; 25: 473-86.
8. Tarng DC, Wen Chen T, Huang TP, Chen CL, Liu TY, Wei YH. Increased oxidative damage to peripheral blood leukocyte DNA in chronic peritoneal dialysis patients. J Am Soc Nephrol 2002; 13: 1321-30.
9. Simmons EM, Langone A, Sezer MT, Vella JP, Recupero P, Morrow JD, et al. Effect of renal transplantation on biomarkers of inflammation and oxidative stress in endstage renal disease patients. Transplantation 2005; 79: 914-19.
10. Cristol JP, Vela C, Maggi MF, Descomps B, Mourad G. Oxidative stress and lipid abnormalities in renal transplant recipients with or without chronic rejection. Trans - plan tation 1998; 65: 1322-8.
11. Miyata T, Kurokawa K, van Ypersele de Strihou C. Relevance of oxidative and carbonyl stress to long term uremic complications. Kidney Int Suppl 2000; 76: 120-5.
12. Leiper J, Vallance P. Biological significance of endogenous methylarginines that inhibits nitric oxide synthases. Cardiovasc Res 1999; 43: 542-8.
13. Zocalli C, Mallamaci F, Tripepi G. Inflammation and atherosclerosis in end stage renal disease. Blood Purif 2003; 21: 29-36.
14. Zoccali C, Bode-Böger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end stage renal disease: A prospective study. Lancet 2001; 358: 2113-17.
15. Boger RH, Zoccali C. ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease. Atheroscler Suppl 2003; 4: 23-8.
16. Fleck C, Janz A, Schweitzer F, Karge E, Schwertfeger M, Stein G. Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in renal failure patients. Kidney Int Suppl 2001; 78: 14-8.
17. Yilmaz MI, Saglam M, Caglar K, Cakir E, Ozgurtas T, Sonmez A, et al. Endothelial functions improve with decrease in asymmetric dimethylarginine (ADMA) levels after renal transplantation. Transplantation 2005; 80: 1660-6.
18. Esposito C, Grosjean F, Torreggiani M, Maggi N, Esposito V, Migotto C, et al. Increased asymmetric dimethylarginine serum levels are associated with acute rejection in kidney transplant recipients. Transplant Proc 2009; 41: 1570-3.
19. Witko-Sarsat V, Friedlander M, Capeillére-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49: 1304-13.
20. Witko-Sarsat V, Gausson V, Descamps-Latscha B. Are advanced oxidation protein products potential uremic toxins? Kidney Int Suppl 2003; 84: 11-4.
21. Akbasli AC, Keven K, Erbay B, Nebioglu S. Changes in oxidative stress in renal graft patients receiving calcineurin inhibitors: cyclosporine versus tacrolimus. Exp Clin Transplant 2012; 10: 439-45.
22. Andreeva IL, Kožemjakin AL, Kiškun AA. Modification of the method of measurement of lipid peroxides in test with thiobarbituric acid. (in Russian) Lab Delo 1988; 11: 41-3.
23. Jain SK, Levine NS, Duett J, Hollier B. Elevated lipid peroxidation levels in red blood cells of streptozotocin-treated diabetic rats. Metabolism 1990; 39(9): 971-5.
24. Goth L. Serum catalase: reversibly formed charge isoform of erythrocyte catalase. Clin Chem 1991; 37(2): 2043-7.
25. Hu ML. Measurement of protein thiol groups and glutathione in plasma. In: Abelson JN, Simon MI (Eds.), Methods in Enzymology. Academic Press, California, 1994; pp. 380-2.
26. Sedlak J, Lindsay RH. Estimation of total protein bound and non-protein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem 1968; 25: 192-205.
27. Navaro-Gonzalvez JA, Garcia-Benayas C, Arenas J. Semiautomated measurement of nitrate in biological fluids. Clin Chem 1998; 44: 679-81.
28. Paroni R, Fermo I, Fiorina P, Cighetti G. Determination of asymmetric and symmetric dimethylarginines in plasma of hyperhomocysteinemic subjects. Amino Acids 2005; 28: 389-94.
29. Campise M, Bamonti F, Novembrino C, Ippolito S, Tarantino A, Cornelli U, et al. Oxidative stress in kidney transplant patients. Transplantation 2003; 76: 1474-8.
30. Raj DS, Lim G, Levi M, Qualls C, Jain SK. Advanced glycation end products and oxidative stress are increased in chronic allograft nephropathy. Am J Kidney Dis 2004; 43(1): 154-60.
31. Güçmen AY, ?ahin E, Koçk H, Tuncer M, Gümüşlü Levels of asymmetric dimethylarginine, nitric oxide and lipid peroxidation markers in patients with end-stage renal disease having peritoneal dialysis treatment. Clinical Biochemistry 2008; 41: 836-40.
32. Quiroz Y, Ferrebuz A, Romero F, Vaziri ND, Rodriguez- Iturbe B. Melatonin ameliorates oxidative stress, inflammation, proteinuria and progression of renal damage in rats with renal mass reduction. Am J Physiol Renal Physiol 2008; 294: 336-444.
33. Slater DA, Bolton CH, Bailey AJ. The importance of lipid derived malondialdehyde in diabetes mellitus. Diabetologia 2000; 43: 550-7.
34. Abarkapa V, Derić M, Stošić Z, SakačV, Davidović A, Eremić N Determinig the relationship between homocysteinemia and biomarkers of inflammation, oxidative stress and functional kidney status in patient with diabetic nephropathy. J Med Biochem 2013 32 131-9.
35. Antolini F, Valente F, Ricciardi D, Fagugli RM. Normalization of oxidative stress parameters after kidney transplant is secondary to full recovery of renal function. Clin Nephrol 2004; 62: 131-7.
36. Zadrazil J, Strebl P, KrejcíK, Horcicka V, HorákP, VostálovíJ, et al. Effect of different calcineurin inhibitors on AOPP and TAS after kidney transplantation. Clinical Biochemistry 2010; 43: 559-65.
37. Sydow K, Fortmann SP, Fair JM, Varady A, Hlatky MA, Go AS, et al. Advance Investigators. Distribution of asymmetric dimethylarginine among 980 healthy, older adults of different ethnicities. Clin Chem 2010; 56: 111-20.
38. Perticone F, Sciacqua A, Maio R, Perticone M, Galiano Leone G, et al. Endothelial dysfunction, ADMA and insulin resistance in essential hypertension. Int J Cardiol 2010; 142: 236-41.
39. Sibal L, Agarwal SC, Home PD, Boger RH. The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. Curr Cardiol Rev 2010; 6: 82-90.
40. Cardounel AJ, Cui H, Samouilov A, Johnson W, Kearns P, Tsai AL, et al. Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. J Biol Chem 2007; 282: 879-87.
41. Echevarría LA, Andrade F. Asymmetric Dimethylarginine, Endothelial Dysfunction and Renal Disease. Int J Mol Sci 2012 13 11288-311.
42. Shi B, Ni Z, Zhou W, Yu Z, Gu L, Mou S, et al. Circulating levels of asymmetric dimethylarginine are an independent risk factor for left ventricular hypertrophy and predict cardiovascular events in pre-dialysis patients with chronic kidney disease. Eur J Intern Med 2010; 21: 444-8.
43. Napora M, Graczykowska A, Próchniewska K, Zdrojewski Z, Całka A, Górny J, et al. Relationship between serum asymmetric dimethylarginine and left ventricular structure and function in patients with end-stage renal disease treated with hemodialysis. Pol Arch Med Wewn 2012; 122: 226-34.
44. Zhang, W, Zhou C, Xie J, Chen B, Chang, L. Serum asymmetric dimethylarginine and endothelial function after renal transplantation. J Cent South Univ (Med. Sci.) 2009; 34: 289-94.
45. Ignjatović AM, Cvetković TP, Pavlović RM, Dordević VM, Milošević ZG, Dordević VB, et al. Endothelial dysfunction, inflammation and malnutrition markers as predictors of mortality in dialysis patients; a multimarker approach. Int Urol Nephrol 2013; 45: 1715-24.
46. CalíLA, Davis PA, Giacon B, Pagnin E, Sartori M, Riegler P, et al. Oxidative stress in kidney transplant patients with calcineurin inhibitor-induced hypertension: effect of ramipril. J Cardiovasc Pharmacol 2002; 40; 625-31.
47. Stílinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway: Role of asymmetric dimethylarginine. Circulation 2001; 104: 2569-75.
48. Hasanoʇlu A, Okur I, Oren AC, Biberoʇlu G, Oktar S, Eminoʇlu FT, et al. The levels of asymmetric dimethyl - arginine, homocysteine and carotid intima-media thickness in hypercholesterolemic children. Turk J Pediatr 2011; 53: 522-7.
49. Cvetković TP, Stefanović NZ, Veliković-Radovanović RM, Paunovic GJ, Dordević VM, Stojanović DR, et al. Gender differences in oxidative and nitrosative stress parameters in kidney transplant patients on tacrolimus-based immunosuppression. Int Urol Nephrol 2013; DOI: 10.1007/s11255-013-0577-x.
50. Kielstein JT, Salpeter SR, Bode-Boeger SM, Cooke JP, Fliser D. Symmetric dimethylarginine (SDMA) as endogenous marker of renal function - a meta-analysis. Nephrol Dial Transplant 2006; 21: 2446-51.
51. Kielstein JT, Martens-Lobenhoffer J, Vollmer S, Bode- Böger SM. L-Arginine, ADMA, SDMA, creatinine, MDRD formula - detour to renal function testing. J Nephrol 2008; 21: 963-5.
52. Kielstein JT, Veldink H, Martens-Lobenhoffer J, Haller H, Burg M, Lorenzen JM, et al. SDMA is an early marker of change in GFR after living-related kidney donation. Nephrol Dial Transplant 2011; 26: 324-8.
53. Klawitter J, Gottschalk S. Immunosuppressant neurotoxicity in rat brain models: oxidative stress and cellular metabolism. Chem Res Toxicol 2010; 23: 608-19.
54. Almawi WY, Melemedjian OK. Negative regulation of nu - clear factor kappa B activation and function by glucocorticoids. J of Molecular Endocrinology 2002; 28: 69-78.
55. VostálovíJ, GalandákovíA, SvobodovíAR, Kajabová M, Schneiderka P, ZapletalovíJ, et al. Stabilization of oxidative stress 1 year after kidney transplantation: effect of calcineurin immunosuppressives. Ren Fail 2012; 34: 952-9.
56. Han SY, Mun KC, Choi HJ, Kwak CS, Bae JH, Suh SI, et al. Effects of cyclosporine and tacrolimus on oxidative stress in cultured mesangial cells. Transplant Proc 2006; 38: 2240-1.
57. Jin KB, Choi HJ, Kim HT, Hwang EA, Suh SI, Han SY, et al. The production of reactive oxygen species in tacro - limus-treated glial cells. Transplant Proc 2008; 40: 2680-1.
58. Perrea DN, Moulakakis KG, Poulakou MV, Vlachos IS, Papachristodoulou A, Kostakis AI. Correlation between oxidative stress and immunosuppressive therapy in renal transplant recipients with an uneventful postoperative course and stable renal function. Int Urol Nephrol 2006; 38: 343-8.
59. Kidokoro K, Satoh M, Nagasu H, Sakuta T, Kuwabara A, Yorimitsu D, et al. Tacrolimus induces glomerular injury via endothelial dysfunction caused by reactive oxygen species and inflammatory change. Kidney Blood Press Res 2012; 35: 549-57.
60. St Peter S, Moss A, Mulligan D. Effects of tacrolimus on ischemia-reperfusion injury. Liver Transpl 2003; 9: 105-16.
61. Hisatomi A, Sakuma S, Fujiwara M, Seki J. Effect of tacrolimus on the cauda epidydymis in rats: analysis of epidydymal biochemical markers or antioxidant defense enzymes. Toxicology 2008; 243: 23-30.
62. Trapp A, Weis MJ. The impact of immunosuppression on endothelial function. J Cardiovasc Pharmacol 2005; 45: 81-7.
63. Vural A, Yilmaz MI, Caglar K, Aydin A, Sonmez A, Eyileten T, et al. Assessment of oxidative stress in the early posttransplant period: comparison of cyclosporine A and tacrolimus-based regimens. Am J Nephrol 2005; 25: 250-5.
64. SzabíAJ, Tulassay T, Melegh B, SzabíT, SzabíA, Vannay A, et al. Hyperhomocysteinaemia and MTHFR C677T gene polymorphism in renal transplant recipients. Arch Dis Child 2001; 85: 47-9.